Login to Your Account

Quark Signs $680M siRNA Drug Deal with Novartis

By Donna Young

Thursday, August 19, 2010
Privately held Quark Pharmaceuticals Inc. stands to bank $680 million, including $10 million up front, under a deal granting Swiss pharma giant Novartis AG an option to obtain an exclusive worldwide license to develop and commercialize QPI-1002, an investigational p53 temporary inhibitor siRNA drug. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription